EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ethionamide versus ethambutol-containing first-line regimens for TB meningitis

Xueyi Chen iD, Carlos E Ruiz-Gonzalez, Yuderleys Masias-Leon, Medha Singh, Madelynn Shambles, Charles A Peloquin, Sanjay K Jain iD

Antimicrobial Agents and Chemotherapy · 05.08.2026 · 70 (8)

DOI: 10.1128/aac.00190-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.08.2026. Verfasst von Xueyi Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Ethambutol, Tuberculosis, Meningeal, Antitubercular Agents, Ethionamide. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ethionamide has emerged as an alternative to ethambutol for the treatment of tuberculous meningitis (TB meningitis). Here, we show that ethionamide- and ethambutol-containing first-line TB regimens achieved similar bactericidal activities in brain tissues and reduction in neuroinflammation in a mouse model of TB meningitis. However, ethionamide, but not ethambutol, achieves brain concentrations above the minimum inhibitory concentration for Mycobacterium tuberculosis .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EthambutolTuberculosis, MeningealAntitubercular AgentsEthionamideMycobacterium tuberculosisAnimalsMiceMicrobial Sensitivity TestsBrainFemale

Stichwörter der Autor:innen

chemotherapyethambutolethionamidetuberculosistuberculous meningitis

Substanzen

EthambutolAntitubercular AgentsEthionamide

Autor:innen und Institutionen

  • Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Infectious Disease Pharmacokinetics Laboratory, Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, Florida, USA.

ORCID-Profile: Xueyi Chen, Sanjay K Jain

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Chen, X., Ruiz-Gonzalez, C. E., Masias-Leon, Y., Singh, M., Shambles, M., Peloquin, C. A., & Jain, S. K. (2026). Ethionamide versus ethambutol-containing first-line regimens for TB meningitis. Antimicrobial Agents and Chemotherapy, 70(8). https://doi.org/10.1128/aac.00190-26

Vancouver

Chen X, Ruiz-Gonzalez CE, Masias-Leon Y, Singh M, Shambles M, Peloquin CA, et al. Ethionamide versus ethambutol-containing first-line regimens for TB meningitis. Antimicrobial Agents and Chemotherapy. 2026;70(8). doi:10.1128/aac.00190-26

BibTeX
@article{Chen2026,
  author = {Chen, Xueyi and Ruiz-Gonzalez, Carlos E and Masias-Leon, Yuderleys and Singh, Medha and Shambles, Madelynn and Peloquin, Charles A and Jain, Sanjay K},
  title = {Ethionamide versus ethambutol-containing first-line regimens for TB meningitis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {8},
  doi = {10.1128/aac.00190-26}
}
Kostenlos starten →